Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Mingxue Fan; Minghao Li; Lipeng Gao; Sicong Geng; Jing Wang; Yiting Wang; Zhiqiang Yan; Lei Yu

doi:10.1186/s13045-017-0519-7

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

J Hematol Oncol. 2017 Aug 29;10(1):151. doi: 10.1186/s13045-017-0519-7.

Authors

Mingxue Fan¹, Minghao Li¹, Lipeng Gao¹, Sicong Geng², Jing Wang¹, Yiting Wang¹, Zhiqiang Yan³, Lei Yu⁴

Affiliations

¹ Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, NO. 3663 Zhongshan Road, Shanghai, 200062, People's Republic of China.
² China Novartis Institutes for Biomedical Research Co., Ltd., GDD/TRD/Chemical and Pharmaceutical Profiling, 5F, Building 3, Novartis Campus 4218 Jinke Rd, Zhangjiang Hi-Tech Park Pudong District, Shanghai, 201203, China.
³ Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, NO. 3663 Zhongshan Road, Shanghai, 200062, People's Republic of China. zqyan@sat.ecnu.edu.cn.
⁴ Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, NO. 3663 Zhongshan Road, Shanghai, 200062, People's Republic of China. yulei@nbic.ecnu.edu.cn.

Abstract

Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.

Keywords: Acute myeloid leukemia; Chimeric antigen receptors; Immunotherapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Chimerism
Humans
Immunotherapy, Adoptive / methods*
Leukemia, Myeloid, Acute / immunology*
Leukemia, Myeloid, Acute / pathology
T-Lymphocytes / metabolism*